IGF Binding Protein 3

SKU 764 Category

Additional information

Response time (working day) | Time to results


Location of analysis | Where is performed



General Information:

IGF-binding protein 3 (IGFBP-3) is a peptide produced in the liver and plays an important role in the transport and bioavailability of IGF (especially IGF-1, a major mediator of growth hormone-anabolic and growth-promoting effects).

About 1% of IGF-2 and IGF-95 are related to IGFBP-3, which is the major transport protein of IGF and which

One of the main functions is to increase the IGF half-life from 8 minutes to several hours. In this way, IGFBP-3 acts as a stabilizer, ensuring a constant level of IGF. Serum concentrations of IGFBP-3 are constant for 24 hours, which is also dependent on growth hormone (GH), so the IGFBP-3 determination is informative for assessing GH (growth hormone) secretion. Unlike GH secretion, which is characterized by diurnal pulse variability, IGFBP-3 and IGF-1 levels show only small fluctuations.

Low serum levels of IGFBP-3 and IGF-1 are observed in growth hormone deficiency or resistance.

These changes acquired in childhood lead to growth retardation. GH deficiency in children may be an isolated abnormality or related to changes in other pituitary hormones. Multiple hormonal insufficiency can be caused by the presence of pituitary or hypothalamic tumors, or the result of radiotherapy and chemotherapy for various malignancies.

In children (growth hormone) resistance to GH is mostly mild to moderate in severity; Causes range from malnutrition to severe systemic diseases such as chronic kidney failure. These individuals may have IGF-1 and IGFBP-3 levels in the reference range. Severe forms of resistance are rare and are usually caused by receptor defects.

In both mild and moderate forms of GH deficiency and GH resistance, it is possible to treat recombinant human GH (rhGH) injections.

The goal of GH replacement therapy in both children and adults is to obtain a reference range of serum IGF-1 and IGFBP-3 values, ideally in the middle third. Higher levels are rarely associated with additional therapeutic benefits and can lead to prolonged side effects.

The prevalence and causes of GH resistance in adults are not well understood, although GH deficiency is most common in patients with pituitary tumors. GH deficiency in adults is associated with decreased muscle mass and increased cardiovascular morbidity and mortality, while replacement therapy remains controversial.

Elevated serum concentrations of IGFBP-3 and IGF-1 indicate excessive secretion of GH (growth hormone) or excessive therapy. Endogenous excess GH is mainly caused by GH-secretory pituitary adenomas and causes gigantism if acquired before cartilage growth closes and subsequent acromegaly. Both conditions are associated with generalized organomegaly, high blood pressure, diabetes, cardiomyopathy, osteoarthritis, compression neuropathy, a small increase in cancer risk, and a decrease in life expectancy.

The advantage of determining IGFBP-3 over IGF-1 is that it has high concentrations at a young age and is used diagnostically in children with growth retardation who have normal growth hormone levels.

IGFBP-3 is a reliable parameter for monitoring treatment efficacy, which is an important test in combination with IGF-1 measurement;

When should we take the test?

Indirect marker of secretion and reception of somatotropic hormone (somatotropin; growth hormone):

  • Diagnosis of growth disorders;
  • Diagnosis of GH (growth hormone) deficiency in adults;
  • Treatment monitoring of human recombinant GH (rhGH) - using growth hormone;
  • Diagnosis and monitoring of acromegaly and gigantism (with IGF-1 and GH).

How to prepare for the test?

Venous blood is required for analysis. The test is required on an empty stomach.

Possible interpretation of the results:

  • Serum IGFBP-3 values ​​can be influenced by several factors: age, sexual development, nutrition, liver and kidney function. IGFBP-3 increases in early childhood and puberty and then decreases slightly in adults.
  • IGFBP-3 concentration decreases during starvation and chronic malnutrition (malnutrition). Serum IGFBP-3 levels are low in liver failure and diabetes but elevated in chronic renal failure.
  • In cases of growth hormone (GH) deficiency or severe resistance, serum IGF-1 and IGFBP-3 levels are lower compared to age data. Patients with incomplete deficiency or mild to moderate resistance may have plasma values ​​in the reference range.
  • Recording elevated IGF-1 and IGFBP-3 values ​​confirms the diagnostics of acromegaly or gigantism in people who have corresponding suspicious signs and symptoms.

Increase in IGFBP-3 levels:

  • Acromegaly, gigantism;
  • Chronic renal failure

Decreased IGFBP-3 levels:

  • Growth hormone deficiency;
  • Laron's dwarf;
  • Malnutrition and prolonged fasting;
  • Liver failure;
  • diabetes

0/5 (0 Reviews)
English EN Georgian KA Russian RU
Call Now Button